Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Invest New Drugs. 2018 Apr 3;36(6):1016–1025. doi: 10.1007/s10637-018-0591-z

Table 2.

Most commonly reported (≥10%) AEs (any cause)a

AE Grade 1,
n (%)
Grade 2,
n (%)
Grade 3,
n (%)
Grade 4,
n (%)
Total, n
(%)
Diarrhea 33 (43) 13 (17) 3 (4) 0 49 (64)
Nausea 42 (55) 4 (5) 1 (1) 0 47 (61)
Fatigue 21 (27) 16 (21) 0 1 (1) 38 (49)
Vomiting 29 (38) 3 (4) 1 (1) 0 33 (43)
Decreased appetite 23 (30) 6 (8) 0 1 (1) 30 (39)
Abdominal pain 13 (17) 4 (5) 3 (4) 0 20 (26)
Constipation 14 (18) 3 (4) 0 0 17 (22)
Hyperglycemia 2 (3) 9 (12) 5 (6) 1 (1) 17 (22)
Rash 8 (10) 8 (10) 1 (1) 0 17 (22)
Weight decreased 12 (16) 5 (6) 0 0 17 (22)
Back pain 11 (14) 3 (4) 1 (1) 0 15 (19)
Dyspnea 10 (13) 3 (4) 2 (3) 0 15 (19)
Dizziness 12 (16) 0 0 0 12 (16)
Pyrexia 10 (13) 2 (3) 0 0 12 (16)
Urinary tract infection 6 (8) 6 (8) 0 0 12 (16)
Cough 9 (12) 0 0 0 9 (12)
Peripheral edema 9 (12) 0 0 0 9 (12)
Headache 7 (9) 0 1 (1) 1 (1) 9 (12)
Dysgeusia 7 (9) 1 (1) 0 0 8 (10)
Mucosal inflammation 7 (9) 1 (1) 0 0 8 (10)

Abbreviations: AE, adverse event.

a

By Common Terminology Criteria for Adverse Events (version 3.0).